ProstaglandinE1 for the medical management of erectile dysfunction

Aid of the study: to evaluate the efficacy of prostaglandin e1 in the management of erectile dysfunction as intracavernosal pharmacotherapy methods: a total of 42 impotent patients received prostaglandine1 intracavernosal injection at urology/andrology out patient department of surgimed hospital & ghurki trust teaching hospital. all gave a previous history of using to papaverine and phentolamine intracavernosal therapy. results: thirty three patients (78.5%) achieved an erection sufficient for sexual intercourse and after a mean follow-up period of 3.8 months,21 patients were continuing to use treatment successfully. the average dose was 14 micrograms (range 2.5 to 30 micrograms). there were no cases of priapism or cavernosal fibrosis and no systemic side effects. slight local discomfort was reported in 8(3.3%) patients. conclusion: prostaglandin (caverject) is a safe and effective intracavernosal therapeutic agent for the treatment of erectile dysfunction. ishii 5 described the use of prostaglandin-e1,and many studies have since showed its efficacy with a reduced incidence of fibrosis and priapism.6'7'8 though it adversely causes severe pain locally. padma-nathan considered prostaglandin as the treatment of choice,alone or in combination with other drugs.